Oculis Holding AG (OCS) is experiencing a notable rise in its stock price following the announcement of positive phase 2 trial results for its lead neuroprotective therapy, OCS-05. The trial, conducted in partnership with Accure Therapeutics, met its primary safety endpoint and key secondary efficacy endpoints without any serious adverse events. This success underscores the potential of OCS-05 in treating a